Counting Tumour Cells in Blood Can Predict Treatment Benefit in Prostate Cancer
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Counting Tumour Cells in Blood Can Predict Treatment Benefit in Prostate Cancer

LUGANO, Switzerland -- July 7, 2008 -- Counting the number of tumour cells circulating in the bloodstream of patients with castration-resistant prostate cancer can accurately predict how well they are responding to treatment, according to new study.

David Olmos, MD, The Royal Marsden NHS Foundation Trust, London, United Kingdom, presented the findings at the ESMO Conference Lugano (ECLU 2008), organised by the European Society for Medical Oncology.

"Our study shows that circulating tumour cell counts could provide information about how patients are responding to therapy earlier than other markers such as prostate-specific antigen or time-to-disease progression," said Dr. Olmos. "We have observed that patients with declining numbers of circulating tumour cells can see a change in their initial prognosis, reflecting a potential benefit from therapy."

Among the 119 patients in the study, researchers found that those with the lowest circulating cell counts had the longest survival on average.

"Cancer cells can be detected in the circulating blood by a range of methods," Dr. Olmos said. "The technique we used in our study is classified as a cytometric approach. We use an antibody that is widely expressed by epithelial cancer cells, and then use a range of cell-staining techniques to ensure it is a cancer cell."

"Because these circulating cells have broken away from either primary tumours or metastatic sites in other parts of the body, they could potentially be used to help study the specific characteristics of the cancer and perhaps personalise therapy."

SOURCE: European Society for Medical Oncology

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities